Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials

Survey Among Healthcare Professionals and MS Patients/Caregivers in Selected European Countries to Evaluate the Knowledge Required for the Safe Use of Mayzent

ClinicalTrials.gov Identifier: NCT05301907

Novartis Reference Number: CBAF312A2006

Last Update: Mar 31, 2022

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

Survey to be completed independently by HCPs (neurologists treating patients with MS and MS specialist nurses) and patients/caregivers.

Condition

Multiple Sclerosis

Phase

Not Given

Overall status

Recruiting

Start date

Dec 02, 2021

Completion date

Sep 30, 2024

Gender

All

Age(s)

18 Years and older (Adult, Older Adult)

Eligibility Criteria

Inclusion Criteria:

Physicians will be considered eligible for the survey if they meet the following screening criteria:

Care for relapsing MS (RMS) patients
Personally prescribed disease modifying therapies to MS patients, and;
Have prescribed Mayzent (siponimod) in at least 1 SPMS patient.

Nurses will be considered eligible for the survey if they:

Provide supportive care for RMS patients
Have initiated and/or managed the use of Mayzent (siponimod) in at least 1 SPMS patient.

Patient inclusion criteria include:

- Have been initiated onto Mayzent (siponimod) to treat their MS since reimbursement

Exclusion Criteria: